Aspen Pharmacare Group is a global specialty and branded multinational pharmaceutical company with a strong presence in both emerging and developed markets. Headquartered in South Africa, Aspen improves the health of patients in more than 150 countries through its high quality, affordable products. The group has a robust and expanding portfolio of anaesthetics, thrombosis, and high potency & cytotoxic products, alongside a diverse range of regional brands. Aspen is committed to manufacturing excellence, supply chain reliability, and sustainable business practices.
Serves as the central hub for global strategic decision-making, corporate governance, financial oversight, and coordination of Aspen's international operations.
Modern, purpose-built corporate campus designed to foster collaboration and reflect the company's global stature. It features contemporary architecture and facilities supporting a dynamic work environment.
The headquarters fosters a professional, performance-driven, and innovative work culture, emphasizing teamwork, ethical conduct, and a commitment to global health and access to medicines.
The Durban headquarters is significant as the operational and strategic core of one of Africa's largest pharmaceutical companies, directing its expansive global network and product portfolio.
Aspen Pharmacare Group supports a wide range of functions globally, including research and development, manufacturing (with facilities in Africa, Europe, Australasia and the Americas), quality assurance, regulatory affairs, commercial operations (sales and marketing), supply chain management, and distribution. The company has a direct commercial presence in over 50 countries and supplies products to more than 150 countries worldwide, covering diverse therapeutic areas such as Anaesthetics, Thrombosis, and High Potency & Cytotoxics.
Aspen Place, 9 Rydall Vale Crescent, La Lucia Ridge Office Estate
Durban
KwaZulu-Natal
South Africa
Address: 3016 Lake Drive, Citywest Business Campus, Dublin 24, Ireland
To manage and expand Aspen's pharmaceutical business across Europe, focusing on specialized therapeutic areas like anaesthetics and thrombosis, and ensuring compliance with regional pharmaceutical regulations.
Address: Building C, Gore Hill Business Park, Cnr Pacific Highway & Shirley Rd, St Leonards NSW 2065, Australia
To provide high-quality, affordable medicines to patients and healthcare professionals in the ANZ region, supporting local healthcare needs and contributing to Aspen's commercial success in the Asia-Pacific.
Address: Building 8, Healthcare Park, Woodlands Drive, Woodmead, Sandton, Johannesburg, South Africa
To oversee and drive Aspen's significant commercial presence in its home market of South Africa and neighboring African countries, managing a broad portfolio of products.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Aspen Pharma Group' leadership includes:
Aspen Pharma Group has been backed by several prominent investors over the years, including:
Aspen Pharmacare Group has seen some changes in its non-executive directorate over the past year, strengthening its board governance and oversight. Key operational executive leadership has remained stable.
Discover the tools Aspen Pharma Group uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Aspen Pharmacare Group typically uses a standard corporate email format, most commonly combining the employee's first initial and last name, or first name and last name, with the company domain 'aspenpharma.com'.
[first_initial][last_name]@aspenpharma.com (e.g., jdoe@aspenpharma.com) or [first_name].[last_name]@aspenpharma.com (e.g. jane.doe@aspenpharma.com)
Format
ssaad@aspenpharma.com
Example
85%
Success rate
Aspen Pharmacare Investor Relations • March 7, 2024
Aspen Pharmacare announced its reviewed provisional group financial results for the six months ended 31 December 2023, reporting a 10% increase in Group revenue to R21.1 billion. Normalised headline earnings per share (NHEPS) from continuing operations rose by 16% to 826.1 cents. The company also declared an interim cash dividend of 178.0 cents per ordinary share....more
Aspen Pharmacare Investor Relations • February 1, 2024
Aspen Pharmacare announced the conclusion of its transaction with Sandoz relating to the divestment of the European commercial rights for its Viatris Clexane and Fraxiparine collaboration products, as well as the related intellectual property and product registrations. This strategic move aligns with Aspen's focus on its core pharmaceutical portfolio and optimizing its European operations....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Aspen Pharma Group, are just a search away.